37924-67-7 Usage
Description
1,2-Benzisoxazole-3-Acetic Acid is an organic compound with the molecular formula C8H5NO3. It is a heterocyclic compound featuring a benzene ring fused to an isoxazole ring, with an acetic acid side chain attached to the isoxazole. 1,2-BENZISOXAZOLE-3-ACETIC ACID is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical structure and properties.
Uses
Used in Pharmaceutical Industry:
1,2-Benzisoxazole-3-Acetic Acid is used as an intermediate in the synthesis of Zonisamide (Z700000), a sulfonamide antiseizure agent. It plays a crucial role in the development of this medication due to its ability to block repetitive firing of voltage-sensitive sodium channels and reduce voltage-sensitive T-type calcium currents.
Used in Anticonvulsant Applications:
1,2-Benzisoxazole-3-Acetic Acid is utilized as an anticonvulsant, demonstrating its potential therapeutic use as an antiepileptic drug. Its chemical structure allows it to interact with specific ion channels in the nervous system, helping to prevent or reduce the frequency of seizures in patients with epilepsy.
Used in Neuroprotective Applications:
1,2-BENZISOXAZOLE-3-ACETIC ACID is also being investigated for its neuroprotective properties, which could be beneficial in the treatment of various neurological disorders. Its ability to modulate ion channels and potentially protect neurons from damage makes it a promising candidate for further research and development in this area.
Used in Neuroresearch:
1,2-Benzisoxazole-3-Acetic Acid serves as a valuable tool in neuroscientific research, particularly in the study of ion channel function and the development of new therapeutic agents for neurological conditions. Its unique chemical structure and properties make it an interesting compound for researchers to explore and understand its potential applications in the field of neuroscience.
Check Digit Verification of cas no
The CAS Registry Mumber 37924-67-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,9,2 and 4 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 37924-67:
(7*3)+(6*7)+(5*9)+(4*2)+(3*4)+(2*6)+(1*7)=147
147 % 10 = 7
So 37924-67-7 is a valid CAS Registry Number.
37924-67-7Relevant articles and documents
Design, Synthesis, and Evaluation of Novel Benzo[ d]isoxazole Derivatives as Anticonvulsants by Selectively Blocking the Voltage-Gated Sodium Channel NaV1.1
Dong, Shiyang,Huang, Xiang,Liu, Hua,Quan, Hexiu,Wan, Pingnan,Wang, Tiantian,Wang, Zengcai,Wang, Zengtao
, (2022/03/15)
Sodium channel blockers are important antiseizure drugs. Since the launch of phenobarbital in 1912, it has a development history of nearly 100 years. However, because of the confounding symptoms, complications, and complex intrinsic pathogenesis of epilepsy, the design and development of blockers specifically targeting sodium channels as antiseizure drugs are difficult and rarely reported. In this study, we designed and synthesized a series of novel benzo[d]isoxazole derivatives as anticonvulsants. Among them, the most potent Z-6b displayed high protection against the MES-induced seizures with an ED50 value of 20.5 mg/kg and a high protective index (TD50/ED50) of 10.3. In addition, Z-6b significantly inhibited NaV1.1 channels in patch-clamp experiments but almost did not inhibit NaV1.2, NaV1.3, and NaV1.6 channels. These findings strongly support the hypothesis that new benzo[d]isoxazole derivatives display anticonvulsant activity by selectively blocking voltage-gated sodium channel NaV1.1, which provides good alternatives for developing selective NaV1.1 channel blockers as antiseizure drugs in the future.
Amino sulfonyl compound, preparation method and uses thereof
-
Paragraph 0161; 0162, (2016/12/01)
The present invention relates to a new amino sulfonyl compound represented by a general formula I, or a tautomer, an enantiomer, a racemate or a pharmaceutically acceptable salt thereof, a preparation method, a pharmaceutical composition, and uses thereof, wherein the compound can be used for treatment of epilepsy, convulsion, obesity, and the like. The general formula I is defined in the specification.
